Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A.

Chung Hua I Hsueh Tsa Chih (Taipei). 1999 Jul;62(7):450-4. Unique Identifier : AIDSLINE MED/99346734
Hsu HC; Chen YF; Ho CH; Department of Medicine, Veterans General Hospital-Taipei, Taiwan,; ROC.

Abstract: BACKGROUND: Plasma-derived factor VIII concentrates used in the treatment of hemophilia A have the potential danger of transfusion-associated viral disease. The safety and efficacy of a recombinant factor VIII preparation for the treatment of this disorder were evaluated in this study. METHODS: We compared the pharmacokinetics of plasma-derived and recombinant factor VIII in 12 previously treated subjects with severe hemophilia A. RESULTS: The recovery and elimination half-lives of the recombinant factor VIII were equal to those of plasma-derived factor VIII. It was well tolerated via parenteral therapy, and only two mild adverse reactions (5%) were reported. No evidence of new viral infection was noted during the study period with the recombinant factor VIII. CONCLUSIONS: The biologic activity of the recombinant factor VIII is comparable with that of plasma factor VIII concentrate. It is safe and efficacious for the treatment of hemophilia A.
Keywords: JOURNAL ARTICLE Adult Factor VIII/ADVERSE EFFECTS/PHARMACOKINETICS/*THERAPEUTIC USE Hemophilia A/*THERAPY Human HIV Seropositivity Male Middle Age Recombinant Proteins/THERAPEUTIC USEKWDjournalarticleadultfactorviii/adverseeffects/pharmacokinetics/KWDtherapeuticusehemophiliaa/KWDtherapyhumanhivseropositivitymalemiddleagerecombinantproteins/therapeuticuse
991030
A99A0922

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .